Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:36 AM
Ignite Modification Date:
2025-12-25 @ 12:36 AM
NCT ID:
NCT00419367
Eligibility Criteria:
Inclusion Criteria:
* Advanced cutaneous T-cell lymphoma on or following two systemic therapies
* Female participants must have a negative serum pregnancy test within 3 days of the first dose of vorinostat
* Female participants must have finished menopause, or are surgically sterilized, or agree to use 2 adequate barrier methods of contraception
* Male participants must agree to use 2 adequate barrier methods of contraception
* To be treated on extension phase of study participant must have been treated on the base study for Protocol 042
Exclusion Criteria:
* Currently receiving any potential histone deacetylase (HDAC) inhibitor (e.g. valproic acid)
* Currently receiving any other systemic therapy for CTCL. Corticosteroids that are similar in strength to 20 mg of prednisone daily are permitted
* Pregnant or lactating
* Known allergy to any component of the study drug
* Eligible for any other study of vorinostat in CTCL patients
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00419367
Study Brief:
Protocol Section:
NCT00419367